8-K: Acurx Pharmaceuticals Holds Annual Meeting, Elects Directors

Acurx Pharmaceuticals announced the results of its Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Summary

• Acurx Pharmaceuticals, Inc. held its Annual Meeting of Stockholders on October 16, 2026.
• A quorum was present, with approximately 52.83% of outstanding shares represented.
• Stockholders elected two Class II directors, David P. Luci and Jack H. Dean, to serve three-year terms expiring in 2029.
• The appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily reporting routine corporate governance matters and director elections with expected outcomes.

Positives

• Successful election of directors, indicating shareholder confidence in current leadership.
• Ratification of the independent auditor, ensuring continued financial oversight.
• Quorum achieved, demonstrating sufficient shareholder participation in governance.
• High percentage of shares voted for the ratification of the independent auditor (2,877,193 out of 2,890,899 represented).

Negatives

• A significant number of broker non-votes (1,629,772) for the director elections, suggesting a portion of shares were not directed by beneficial owners.
• A small number of shares voted against the ratification of the independent auditor (8,473).

Future Outlook

No specific forward-looking statements or guidance were provided in this filing, which pertains to the results of a shareholder meeting.

Management Comments

• The filing details the voting results for proposals considered at the Annual Meeting.
• The company's common stock is registered on The Nasdaq Stock Market LLC under the trading symbol ACXP.

Industry Context

StockSavvy.ai notes that annual meetings and the election of directors are standard corporate governance procedures across the pharmaceutical industry, essential for maintaining investor confidence and regulatory compliance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Confirmation of board leadership and continued independent financial oversight.
• Management: Reinforces their positions through director elections.
• Auditors: Continuation of services by CohnReznick LLP.

Next Steps

• The newly elected directors will serve their three-year terms expiring in 2029.
• CohnReznick LLP will continue as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Dates

Keywords

Annual Meeting, Stockholders, Directors, Independent Auditor, Corporate Governance, Shareholder Vote